Tim Oldham
Tim Oldham grows and globalises innovative life sciences companies, with a particular focus on cell and gene therapies. He has more than 15 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is a former CEO and Managing Director of Cell Therapies Pty Ltd, a leading Asia Pacific provider of manufacturing and distribution of cell-based therapeutics and was President of Asia Pacific for Hospira Inc. (2007 to 2012), having held a variety of senior management roles with Mayne Pharma (2002 to 2007) prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies. Prior to this, Dr. Oldham was an engagement manager with McKinsey & Co (1997 to 2001). He has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Board Director of the Alliance for Regenerative Medicine, and a Director of Respiri Ltd (ASX: RSH). He is a member of AusBiotech’s Regenerative Medicine Advisory Group and a Director of Acrux Ltd (ASX:ACR).
Abstracts this author is presenting: